Takeda To Pay Keros Therapeutics $20 Million As Late-Stage Blood Disorder Trial Doses First Patient
Keros plans to pass 25% of the net proceeds to stockholders after the milestone triggers under its Takeda license agreement.
Keros Therapeutics will collect a $20 million development milestone from partner Takeda after the first patient was dosed in a late-stage trial testing elritercept in myelofibrosis patients, the company disclosed Tuesday in an 8-K filed with the SEC. The payment triggers a planned distribution to stockholders, with Keros committing to pass along 25% of the net cash proceeds once the money arrives.
What The Filing Says
The 8-K, signed by Jasbir S. Seehra, Ph.D., Keros's President and Chief Executive Officer, discloses that the milestone falls under the global license agreement Keros struck with Takeda Pharmaceuticals U.S.A. That agreement, which became effective on January 16, 2025, covers the development, manufacturing, and commercialization of elritercept everywhere in the world outside mainland China, Hong Kong, and Macau.
The triggering event is the dosing of the first patient in the ELRiSE MF trial. According to the press release attached as an exhibit to the filing, ELRiSE MF is a late-stage, multicenter, double-blind, randomized trial comparing elritercept against a placebo in patients who have both myelofibrosis and anemia and are already on concurrent ruxolitinib therapy.
"The milestone marks another important step forward for the elritercept program," Seehra said in the release. "We are grateful to our partner Takeda for their dedication to bringing this important potential new treatment to patients in need."
Elritercept is designed to treat low blood cell counts — including anemia and thrombocytopenia — in patients with myelodysplastic syndromes and myelofibrosis. Keros describes it as an engineered ligand trap built from a modified binding domain of a protein receptor fused to a portion of a human antibody.
The Broader Takeda Deal And What Remains On The Table
Tuesday's milestone is the first development payment Keros has collected since the Takeda agreement launched. When the license became effective in January 2025, Keros received a $200 million upfront cash payment from Takeda in February 2025.
Beyond that upfront sum and the $20 million now incoming, the agreement leaves Keros eligible for development, commercial, and sales milestones with the potential to exceed $1.1 billion in total. Keros is also entitled to tiered royalties on net sales of elritercept, though no royalties are payable until the drug reaches the market.
The size of the remaining milestone pool means the ELRiSE MF trial carries significant financial weight beyond the current payment: each successive clinical and regulatory gate could unlock additional tranches from that $1.1 billion-plus ceiling.
The Stockholder Distribution
Keros said it plans to distribute 25% of the net cash proceeds from the $20 million milestone to its stockholders after it receives the payment. The company has not specified a timeline for when it expects to receive the funds or when the distribution would follow.
KROS shares edged down 0.53% to $11.20 in Friday trading, according to market data.
Keros's other lead program, rinvatercept, is being developed separately for Duchenne muscular dystrophy and amyotrophic lateral sclerosis and is not part of the Takeda agreement.
Investors tracking the elritercept program will watch for enrollment progress and any interim data from the ELRiSE MF trial, alongside the timing of the stockholder distribution tied to the $20 million milestone receipt.
Sources
- 8-K Filing — Keros Therapeutics, Inc. (KROS) — SEC EDGAR
- Exhibit exhibit99192926pr.htm — Keros Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Keros Therapeutics to Receive Additional Development — globenewswire.com
